JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

Search

Eli Lilly and Co.

Deschisă

SectorSănătate

766.89 0.4

Rezumat

Modificarea prețului

24h

Curent

Minim

759.04

Maxim

772.32

Indicatori cheie

By Trading Economics

Venit

-6.1B

2.8B

Vânzări

-804M

13B

P/E

Medie Sector

60.989

51.198

EPS

3.34

Randament dividend

0.8

Marjă de profit

21.678

Angajați

47,000

EBITDA

-2B

4.2B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+30.26% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.80%

2.40%

Următoarele câștiguri

6 aug. 2025

Data viitoare de dividende

10 iun. 2025

Următoarea dată ex-dividende

14 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-157B

671B

Deschiderea anterioară

766.49

Închiderea anterioară

766.89

Sentimentul știrilor

By Acuity

36%

64%

119 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Eli Lilly and Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 mai 2025, 14:41 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

1 mai 2025, 11:24 UTC

Câștiguri

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

29 mai 2025, 01:00 UTC

Top știri

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New -2-

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 mai 2025, 14:02 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 mai 2025, 14:01 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 mai 2025, 14:00 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 mai 2025, 14:00 UTC

Achiziții, Fuziuni, Preluări

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 mai 2025, 14:08 UTC

Câștiguri

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 17:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 mai 2025, 17:01 UTC

Top știri

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mai 2025, 13:56 UTC

Câștiguri

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mai 2025, 11:18 UTC

Câștiguri

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mai 2025, 09:30 UTC

Top știri

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 mai 2025, 20:30 UTC

Top știri

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 mai 2025, 04:05 UTC

Achiziții, Fuziuni, Preluări

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 mai 2025, 21:07 UTC

Market Talk

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 mai 2025, 14:07 UTC

Câștiguri

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 12:47 UTC

Câștiguri

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1 mai 2025, 12:00 UTC

Top știri

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1 mai 2025, 11:58 UTC

Câștiguri

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 11:06 UTC

Câștiguri

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 10:48 UTC

Câștiguri

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1 mai 2025, 10:48 UTC

Câștiguri

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1 mai 2025, 10:45 UTC

Câștiguri

Eli Lilly 1Q Adj EPS $3.34 >LLY

1 mai 2025, 10:45 UTC

Câștiguri

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1 mai 2025, 10:45 UTC

Câștiguri

Eli Lilly 1Q Net $2.76B >LLY

Comparație

Modificare preț

Eli Lilly and Co. Așteptări

Obiectiv de preț

By TipRanks

30.26% sus

Prognoză pe 12 luni

Medie 997.6 USD  30.26%

Maxim 1,190 USD

Minim 700 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEli Lilly and Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

17

Cumpărare

2

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 884.54Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Strong Bearish Evidence

Sentiment

By Acuity

119 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.